Mayo Clinic researchers load CAR-T cells with oncolytic virus to treat solid cancer tumors
Researchers at Mayo Clinic's Center for Individualized Medicine have developed an immunotherapy approach that combines CAR-T cell treatment with a cancer-killing virus to target and cure solid cancer tumors more efficiently.
Researchers at Mayo Clinic's Center for Individualized Medicine have developed an immunotherapy approach that combines CAR-T cell treatment with a cancer-killing virus to target and cure solid cancer tumors more efficiently. CAR-T cells, which are programmed to hunt for antigens on cancer cells, are loaded with an oncolytic virus in this combined strategy described in Science Translational Medicine. Oncolytic viruses are viruses that naturally infect cancer cells and destroy them. They may be made to target cancer cells preferentially, or they can increase effectively in cancer cells spontaneously. According to the research, CAR-T cells may be able to transport the oncolytic virus to the tumor.
The virus may invade tumor cells, multiply, and trigger a robust immune response. The treatment approach tackles two fundamental issues that make CAR-T cell therapy alone challenging to treat solid tumors. For starters, the oncolytic virus has the ability to tear down the molecular barrier that certain solid tumors deploy to protect themselves from immune system assault. Second, the virus can infiltrate the cancer cells' core – a near-impossible task for immune cells alone, often losing their effectiveness.
According to the researchers, the combo therapy also created an immunological memory phenotype against the tumor. Dr. Vile and his colleagues used mice models to administer the dual treatment intravenously to treat high-grade glioma in children and adults and skin melanoma. They discovered that the combined treatment resulted in high cure rates in numerous tumor locations with little harm. According to the researchers, it also seemed to protect cured mice against recurrence of tumors.
ارسال به دوستان